Form 4: Vertex Pharmaceuticals Director Upadhyay Reports Stock Transactions

Director Suketu Upadhyay reports acquisition and disposition of Vertex Pharmaceuticals stock and deferred stock units.

Summary

• On May 1, 2025, Suketu Upadhyay, a director at Vertex Pharmaceuticals, reported acquiring 796 shares of common stock through a restricted stock unit award.
• These restricted stock units vest on the first anniversary of the grant date.
• Upadhyay also disposed of 1,001 shares of common stock in exchange for 1,001 deferred stock units, as part of the company's deferred compensation plan.
• Following these transactions, Upadhyay beneficially owns 2,354 shares of common stock and 2,475.603 deferred stock units.
• Each deferred stock unit represents one share of common stock, payable upon termination of service, a change of control, disability, or death.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director, indicating a neutral sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding insider activity.
• The deferred compensation plan may impact employees participating in the plan.

Key Dates

Keywords

Vertex Pharmaceuticals, VRTX, Suketu Upadhyay, Form 4, Stock Transaction, Deferred Stock Units, Restricted Stock Units, Director